Shanxi Zhendong Pharmaceutical Asset Resilience Ratio
Shanxi Zhendong Pharmaceutical asset resilience ratio. Shanxi Zhendong Pharmaceutical (300158) has an Asset Resilience Ratio of 10.74% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See how many days can Shanxi Zhendong Pharmaceutical fund operations to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Shanxi Zhendong Pharmaceutical (2016–2024)
Asset resilience ratio of Shanxi Zhendong Pharmaceutical from 2016 to 2024. This chart shows how Shanxi Zhendong Pharmaceutical's Asset Resilience Ratio has changed over time. Read Shanxi Zhendong Pharmaceutical (300158) total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Shanxi Zhendong Pharmaceutical's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see 300158 asset base.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥484.61 Million | 10.74% |
| Total Liquid Assets | CN¥484.61 Million | 10.74% |
Asset Resilience Insights
- Moderate Liquidity: Shanxi Zhendong Pharmaceutical has 10.74% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Shanxi Zhendong Pharmaceutical Industry Peers by Asset Resilience Ratio
Compare Shanxi Zhendong Pharmaceutical's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262 |
Drug Manufacturers - Specialty & Generic | 26.45% |
|
Tibet Rhodiola Pharmaceutical Holding Co
SHG:600211 |
Drug Manufacturers - Specialty & Generic | 11.84% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
|
Bide Pharmatech Co. Ltd. A
SHG:688073 |
Drug Manufacturers - Specialty & Generic | 9.46% |
|
Jianmin Pharmaceutical Group Co Ltd
SHG:600976 |
Drug Manufacturers - Specialty & Generic | 20.61% |
|
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365 |
Drug Manufacturers - Specialty & Generic | 30.38% |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078 |
Drug Manufacturers - Specialty & Generic | 0.42% |
Shanxi Zhendong Pharmaceutical Asset Resilience Ratio by Year (2016–2024)
Shanxi Zhendong Pharmaceutical asset resilience ratio by year from 2016 to 2024. The table below shows the annual Asset Resilience Ratio data for Shanxi Zhendong Pharmaceutical.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 19.86% | CN¥989.62 Million ≈ $144.81 Million |
CN¥4.98 Billion ≈ $729.13 Million |
-3.57pp |
| 2023-12-31 | 23.43% | CN¥1.45 Billion ≈ $211.88 Million |
CN¥6.18 Billion ≈ $904.40 Million |
-7.40pp |
| 2022-12-31 | 30.82% | CN¥2.02 Billion ≈ $295.48 Million |
CN¥6.55 Billion ≈ $958.60 Million |
-13.46pp |
| 2021-12-31 | 44.28% | CN¥4.47 Billion ≈ $654.06 Million |
CN¥10.09 Billion ≈ $1.48 Billion |
+43.99pp |
| 2019-12-31 | 0.29% | CN¥20.00 Million ≈ $2.93 Million |
CN¥6.92 Billion ≈ $1.01 Billion |
-0.53pp |
| 2018-12-31 | 0.82% | CN¥59.21 Million ≈ $8.66 Million |
CN¥7.21 Billion ≈ $1.06 Billion |
+0.15pp |
| 2017-12-31 | 0.67% | CN¥51.20 Million ≈ $7.49 Million |
CN¥7.61 Billion ≈ $1.11 Billion |
-0.34pp |
| 2016-12-31 | 1.02% | CN¥69.86 Million ≈ $10.22 Million |
CN¥6.87 Billion ≈ $1.01 Billion |
-- |
About Shanxi Zhendong Pharmaceutical
Shanxi Zhendong Pharmaceutical Co.,Ltd, together with its subsidiaries, engages in the research, development, production, and sales of pharmaceutical drugs in China. It offers drugs for various fields, including tumors, dermatology, digestion, urology, and cardio-cerebral drugs. The company also provides Chinese herbal medicines. Shanxi Zhendong Pharmaceutical Co.,Ltd was founded in 1995 and is b… Read more